Related Experiment Video

Updated: Jul 29, 2025

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

19.7K

Synergistic Effect of Metformin and Lansoprazole Against Gastric Cancer through Growth Inhibition

Hsiao-Wei Kao1, Kuo-Wang Tsai2, Wen-Chang Lin1,3

  • 1Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, R.O.C.

International Journal of Medical Sciences
|May 22, 2023
PubMed

Insights

Metformin and lansoprazole show significant anticancer effects against human gastric cancer cells. Combining these drugs offers a synergistic approach, suggesting a potential new treatment for stomach cancer.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Cancer is associated with metabolic disorders and genetic mutations.
  • Metformin, a type 2 diabetes drug, exhibits anti-cancer properties in preclinical models.
  • Proton pump inhibitors like lansoprazole are used for gastroesophageal reflux disease.

Purpose of the Study:

  • To investigate the effects of metformin on human gastric cancer cell lines.
  • To evaluate the synergistic anticancer effects of metformin and lansoprazole.
  • To explore a potential new treatment strategy for stomach cancer.

Main Methods:

  • Treatment of human gastric cancer cell lines with metformin and lansoprazole.
  • Dose-dependent analysis of drug efficacy.
  • Assessment of cell cycle progression and apoptosis induction.
  • Evaluation of synergistic effects at low drug concentrations.

Main Results:

  • Metformin and lansoprazole significantly inhibit gastric cancer cell growth in a dose-dependent manner.
  • The drugs suppress cell cycle progression and induce apoptosis.
  • A synergistic inhibitory effect on AGS cell growth was observed with low concentrations of both drugs.

Conclusions:

  • Metformin and lansoprazole demonstrate potent anticancer activity against gastric cancer cells.
  • The combination therapy exhibits synergistic effects, enhancing growth inhibition.
  • These findings support a novel and safe treatment protocol for stomach cancers.
Keywords:
Gastric CancerMetformin and LansoprazoleSynergistic Effect

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

786
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
241
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
4.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
217
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
220